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Abstract
Background: Stem cells isolated from amniotic fluid are known to be able to differentiate into
different cells types, being thus considered as a potential tool for cellular therapy of different human
diseases. In the present study, we report a novel single step protocol for the osteoblastic
differentiation of human amniotic fluid cells.
Results: The described protocol is able to provide osteoblastic cells producing nodules of calcium
mineralization within 18 days from withdrawal of amniotic fluid samples. These cells display a
complete expression of osteogenic markers (COL1, ONC, OPN, OCN, OPG, BSP, Runx2) within
30 days from withdrawal. In order to test the ability of these cells to proliferate on surfaces
commonly used in oral osteointegrated implantology, we carried out cultures onto different test
disks, namely smooth copper, machined titanium and Sandblasted and Acid Etching titanium (SLA
titanium). Electron microscopy analysis evidenced the best cell growth on this latter surface.
Conclusion: The described protocol provides an efficient and time-saving tool for the production
of osteogenic cells from amniotic fluid that in the future could be used in oral osteointegrated
implantology.
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Background
Amniotic Fluid Cells (AFCs) can be classified in epith-
eloid E-type cells, amniotic fluid specific AF-type cells and
fibroblastic F-type cells (1). In recent years, different
reports have demonstrated that presence in human amni-
otic fluid of stem cells (AFS) able to differentiate into mul-
tiple lineages [1-8]. Very recently, the ability of clonal AFS
to produce cell types inclusive of all embryonic germ lay-
ers was demonstrated [9,10]. Unlike embryonic stem
cells, AFS have been showed to be not tumorigenic after
transplantation in mice [9]. As a consequence, several
studies have suggested the usefulness of these cells for
therapeutic purposes [11-16]. Osteoblastic cells derived
from AFS could be useful for bone regeneration after trau-
matic or degenerative damage [17,18]. In fact, osteoblastic
progenitors obtained from amniotic fluid could be used
to engineer the craniofacial structures whose natural
development is regulated by mesenchymal cells originat-
ing from the neural crest, avoiding long and difficult ther-
apies of bone augmentation with intra-oral or extra oral
donor site [19,20]. In order to obtain the best results in
craniofacial tissue engineering, great relevance is assumed
by the use of scaffolds able to accommodate cell growth
and tissue genesis. To date, implants with different surface
treatments are investigated to define the best surface mor-
phology for a good osteoblastic cell proliferation and
osseointegration around implant [21-25].
The aim of the present study is to evaluate the ability of
human AFS to differentiate into osteogenic cells using a
novel single step culture protocol, and to test their growth
ability on different implant surfaces.
Results
Osteoblastic differentiation was obtained in the present
study using two different culture protocols of amniotic
fluid cells. In the first protocol (Protocol 1), Amniotic
Fluid Mesenchymal Stem cells (AFMSCs) were transferred
in osteogenic medium at passage 6, while in the second
protocol (Protocol 2), pellets of amniotic fluid samples
were directly resuspended in osteogenic medium without
the selection of AFMSCs.
A flow chart describing the different timing of the two pro-
tocols used in this study is reported in Figure 1.
In Protocol 1, seven days after the initiation of the primary
culture, fibroblast-like cells appeared both isolated and as
colonies in the culture flask (Figure 2a). After 20–22 days
of culture, at 70–80% confluence (Figure 2b), cells were
treated with trypsin and EDTA and collected. RT-PCR
analysis, carried out on RNA extracted from the cells at
this stage, evidenced the presence of genes previously
reported as expressed in AFMSCs [26], namely SDF1,
CXCR4, Oct-4, SCF, GATA-4, Vim, FGF-5, Pax-6, NCAM,
AFP, BMP-2 (Figure 3). Cells collected at day 20–22 were
transferred and cultured in the osteogenic medium. After
18 days of culture in osteogenic medium (day 40 from
withdrawal), the cells showed 70–75% confluence, and
the presence of aggregates or nodules of calcium mineral-
ization was appreciable. The number and size of these
aggregates increased in the following days. Cells directly
cultured in osteogenic medium (Protocol 2) reached 70–
75% confluence after 18 days from withdrawal, and
became over confluent in the following days (Figure 2c).
In the following days the appearance of the first aggregates
of calcium mineralization was observed (Figure 2). Ali-
zarin Red staining confirmed the presence of biomineral-
ization (Fig. 2e). An increase in the number and size of
aggregates during the time was observed also in these cul-
tures (Figure 2f). Cell count carried out on 5 cultures per-
formed with protocol 2 at day 30 from withdrawal
demonstrated the presence of cell number ranging from
8,9 × 106 9,7 × 106 cells.
RT-PCR analysis carried out at day 50 (protocol 1) or 30
(Protocol 2) from withdrawal, showed expression of
COL1, ONC, OPN, OCN, OPG, BSP and Runx2, typical
markers of the osteogenic differentiation (Figure 4). The
same genes were not expressed in fresh amniotic fluid
samples, analyzed as negative control (not showed).
In order to evaluate the growth ability of osteoblastic cells
obtained by Protocol 2 on different surfaces commonly
used in oral implantology, cultures were carried out on
smooth copper, machined titanium and Sandblasted and
Acid Etching titanium (SLA titanium) test disks, and eval-
uated using Electron Scanning Microscopy. Titanium is
Flow chart showing the different steps of the two protocols  for the production of osteogenic cells from amniotic fluid Figure 1
Flow chart showing the different steps of the two 
protocols for the production of osteogenic cells from 
amniotic fluid.BMC Biotechnology 2009, 9:9 http://www.biomedcentral.com/1472-6750/9/9
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universally considered as the first-rate material for oral
osseointegrated implantology. Additional treatments on
commercially pure (c.p.) titanium surface provide further
enhancement of bone-to-implant contact, thus reducing
the osseointegration period, improving treatment out-
come and increasing applicability to poor bone quality.
The investigation of implants with different surface treat-
ments, both in vitro and in vivo, is a crucial point in order
to define the surface morphology which could permit a
good osteoblastic cell proliferation and osseointegration
around implant. In our experiments, adherent cells were
not detected on smooth copper surface (negative control)
at day 3, while different behaviour of osteoblastic-like
cells were observed on machined titanium and SLA tita-
nium surfaces. On machined titanium surfaces, few
adherent cells were observed around the titanium disk.
On the contrary, adherent cells were found to cover the
whole surface of SLA titanium disk (Figure 5a). Cell aggre-
gates were arranged almost uniformly and formed a single
layer cell culture on the disk surface (Figure 5b). At high
magnification philophodia surrounding cell surfaces were
clearly visible (Figure 5c–d).
In order to evaluate the mitotic stability of cells, cytoge-
netic investigation was carried out on Protocol 2 cultures
at day 30, showing normal diploid karyotype in all the
investigated metaphases.
Discussion
Different protocols have been reported in literature for the
differentiation of osteogenic cells starting from amniotic
fluid. Some authors reported the use of immunoselection
with c-Kit specific antibodies in order to isolate AFS start-
ing from confluent human amniocentesis cultures, fol-
lowed by proliferation of AFMSCs under appropriate
culture conditions, and finally osteoblastic differentiation
after several days of culture [8,9]. On the other hand,
other groups cultured unselected amniotic fluid cells in
a) Fibroblast-like cells (AFMSCs) obtained after 7 days of  amniotic fluid culture (Protocol 1); b) Confluence of AFMSCs  after 22 days of amniotic fluid culture (Protocol 1); c) over  confluent osteoblastic cells after 20 days of amniotic fluid cul- ture in osteogenic medium (Protocol 2); d) nodules of cal- cium mineralization, osteoblastic cells (Protocol 2); e)  Alizarin Red Staining of osteoblastic cells obtained after 22  days of amniotic fluid culture Figure 2
a) Fibroblast-like cells (AFMSCs) obtained after 7 
days of amniotic fluid culture (Protocol 1); b) Conflu-
ence of AFMSCs after 22 days of amniotic fluid cul-
ture (Protocol 1); c) over confluent osteoblastic cells 
after 20 days of amniotic fluid culture in osteogenic 
medium (Protocol 2); d) nodules of calcium minerali-
zation, osteoblastic cells (Protocol 2); e) Alizarin Red 
Staining of osteoblastic cells obtained after 22 days of 
amniotic fluid culture. Red spots indicate the presence of 
calcium mineralization; f) Alizarin Red Staining of osteoblastic 
cells after 30 days of amniotic fluid culture. Note the increase 
in the number and size of aggregates of calcium mineraliza-
tion.
RT-PCR analysis of AFMSCs at day 20 of culture (protocol 1) Figure 3
RT-PCR analysis of AFMSCs at day 20 of culture 
(protocol 1).
RT-PCR analysis of osteoblastic cells at 30 days of culture  (protocol 2) Figure 4
RT-PCR analysis of osteoblastic cells at 30 days of 
culture (protocol 2). Line 1 = ONC; Line 2 = Runx2; Line 
3 = OCN; Line 4 = BSP; Line 5 = OPN; Line 6 = COL I; Line 
7 = OPG; Line 8 = GAPDH; Line 9 = 100 bp molecular 
weight marker.BMC Biotechnology 2009, 9:9 http://www.biomedcentral.com/1472-6750/9/9
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media allowing the proliferation of AFMSCs, and subse-
quently induced their differentiation in osteoblastic cells
[1,4,5].
In the present study, we demonstrated the ability of
human AFS to differentiate into osteogenic cells using a
single step culture procedure, allowing a 20 days reduc-
tion of the culture time as compared to previously
reported protocols. This could represent an important
point in the view of a possible therapeutic application of
these cells. Amniotic fluid samples, directly resuspended
in osteogenic medium without the selection of AFMSCs,
were able to produce osteogenic cells after 18 days from
the withdrawal as demonstrated by Alizarin Red staining.
RT-PCR analysis showed the full expression of all osteo-
genic markers typical of late stage osteoblasts after 30 days
of colture, while the same expression pattern is showed
after 50 days from withdrawal by cells obtained using con-
ventional protocols. Cytogenetic investigation, carried out
at day 30 on cells obtained by the single step protocol,
showed normal diploid karyotype in all the investigated
samples, thus confirming the mitotic stability of cells
obtained using this procedure. Cell count performed on
cultures carried out with protocol 2 showed the presence
at day 30 from withdrawal of about 9,7 × 106 cells starting
from as little as 2–3 ml of amniotic fluid. Although the
direct culture of AFS cells in osteogenic medium likely
induces a complete cell differentiation within 30 days,
with arrest of cell proliferation, the amount of cells
obtained with this protocol fits well with the cell number
required for preclinical studies in animal models and for
local transplant in human. Since this latter approach
would likely represent the gold standard for a future clin-
ical application in odontoiatric and orthopaedic implan-
tology, the cell number obtained using our direct protocol
appears to be sufficient for future local therapeutic pur-
poses.
In order to test the ability of osteoblastic cells obtained
from amniotic fluid to proliferate onto surfaces com-
monly used for craniofacial implantology, and to evaluate
their usefulness for tissue engineering, we tested these
cells on disks with machined titanium and SLA titanium
surfaces. Electron microscopy observation showed a good
growth and adherence of osteoblastic cells on this latter
surface. This result indicates the excellent biocompatibil-
ity of osteoblastic cells obtained from amniotic fluid with
SLA titanium scaffolds currently utilized in dental
implant.
Conclusion
The protocol described in the present study shows the
ability of producing osteoblastic cells from amniotic fluid
samples in a very short time, being these cells fully differ-
entiated within one month from withdrawal. Although
osteoblastic progenitors can be successfully obtained
from bone marrow stromal cells, the use of amniotic fluid
as a source of these cells is of relevance since AFS can be
easily obtained from routine clinical amniocentesis speci-
mens that would otherwise be discarded. Thus, it is possi-
ble to suggest that banking of these stem cells will provide
in the future a relevant source both for autologous therapy
in the adulthood and for the transplant in HLA matched
recipients.
Methods
Isolation and culture of mesenchymal stem cells from 
amniotic fluid (AFMSCs)
Amniotic fluid samples were obtained from 11 women
undergoing amniocentesis for prenatal diagnosis at 16–
19 weeks of pregnancy after written informed consent.
The study has been approved by the Ethics Committee for
Biomedical Research of the "G. d'Annunzio" University,
Chieti. For each sample, 2–3 ml of amniotic fluid, corre-
sponding to a cell number ranging from 2 × 103 to 2 × 106
[1] were centrifuged for 10 minutes at 1800 rpm. Pellets
were resuspended in Iscove's modified Dulbecco's
medium supplemented with 20% FBS, 100 U/ml penicil-
lin, 100 μg/ml streptomycin (Sigma), 2 mM L-glutamine,
5 ng/ml basic fibroblast growth factor (FGF2) and incu-
bated at 37°C with 5% humidified CO2. After 7 days,
non-adherent cells were removed and the adherent cells
allowed to growth in the same medium, which was
changed each 4 days. When culture reached confluence
(about 20 days after the primary culture), cells were
treated with 0,05% trypsin and 0,02% EDTA, then
counted and replaced in 25 cm2 culture flasks.
Scanning Electron Microscope analysis of osteoblastic cells  cultured on SLA titanium disks Figure 5
Scanning Electron Microscope analysis of osteoblas-
tic cells cultured on SLA titanium disks. a) 22×, b) 
500×: adherent cells covering the whole surface of SLA tita-
nium disk; c) 1250×, d) 1250×: evidence of philophodia sur-
rounding cell surfaces.BMC Biotechnology 2009, 9:9 http://www.biomedcentral.com/1472-6750/9/9
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Osteogenic differentiation
Two different culture protocols were used for osteogenic
differentiation of amniotic fluid cells. In the first protocol
(Protocol 1), AFMSCs cells at passage 6 were transferred in
osteogenic medium consisting of the above described
medium with the addition of 150 μg/ml β Glycerophos-
phate, 50 μg/ml ascorbic acid, and 10-8 M dexamethasone.
In the second protocol (Protocol 2), pellets of amniotic
fluid samples were directly resuspended in osteogenic
medium in 75 cm2 flasks without the selection of AFM-
SCs. At day 8 from withdrawal, colony forming cells were
counted, showing a number ranging from 20 to 20.000 in
the different cultures. To visualize calcium sediments,
cells treated with Protocol 2 were stained at different times
(19, 22 and 30 days from withdrawal) with Alizarin Red S
solution, according to Gregory et al. [27]. Mineralization
was demonstrated by the presence of red depositions. All
reagents used for cells culture and staining were purchased
by Sigma-Aldrich (Milano, Italy)
Culture on different surfaces
Three test disks (diameter 10 mm, thickness 5 mm) for
each different surface, namely smooth copper, machined
titanium and Sandblasted and Acid Etching titanium (SLA
titanium), were used in this study Geometric surface mor-
phology of Machined Titanium test disks was obtained
with turning machined treatment with formation of tita-
nium micro-parallel walls. Sandblasted and Acid Etching
titanium (SLA titanium) test disks were obtained by TiO2
particles being applied to the surface and two phases of
etching with fluoridric acid followed by a second acid
attack by sulphuric-hydrochloric acid with irregular dis-
tributed porosity structure of micro-deep valleys alter-
nated to elevated sharp crests. To preliminary characterize
the surface morphology, test disks have been evaluated by
means of Scanning Electron Microscopy (SEM) imaging
(LEO 435 VP, Cambridge, UK) at about 15–20 kV, high
vacuum mode. The surface roughness of the specimens
were measured with a stylus profilometer (ANSI/ASME
B46.1 1–2002) and a gloss meter (45°-90° sensor angle,
1–10 range, DIN 16537). Differences between treatment
groups were evaluated using an analysis of variance at the
95% confidence level and parametric Newman-Keuls
multiple comparison test at p = 0.05 significance level.
After differentiation, at day 15, osteoblastic cells obtained
using protocol 2 were divided in three groups and 3,7 ×
104 cells were seeded onto each of the three different test
disks. When 70% confluence was observed (after 2–3 days
of culture), cells were prepared and analysed by SEM. The
entire culture protocol on test disks was repeated two
times.
Scanning Electron microscopy
For SEM analysis, specimens cells were fixed in 2% gluter-
aldehyde in 0.1 M cacodylate buffer (pH 7.4). To preserve
the lipid structures, specimens were gently washed in 0.2
M cacodylate buffer (pH 7.4) with the addition of 0.15 M
saccharose for three changes every 20 minutes, post-fixed
in 1% osmium tetroxide at room temperature for 1 hours,
then given two quick changes of the previous buffer and
gradually dehydrated in increasing ethanol concentra-
tions (from 25 to 100%, 15% steps). Samples were then
carried through critical point drying (CPD) according to
standard procedure using liquid carbon dioxide, mounted
on aluminium stubs, gold-sputtered and observed with a
Philips XL20 Scanning Electron Microscope (SEM Philips
XL 20; FEI, Eindhoven, The Netherlands) at 20 KV, high
vacuum mode. Images were stored in TIF format with
1024 × 768 Grid of Pixels
RT-PCR
Total RNA was isolated using the SV Total RNA Isolation
System Kit (Promega, Milano, Italy) from: a) AFMSCs
cells after 20 days culture in standard medium (protocol
1); b) differentiated cells after 30 days in osteogenic
medium (protocols 1 and 2). RNA from fresh amniotic
fluid was also used as a control. One μg of total RNA was
reverse transcribed using RETROscript Kit (Ambion,
Milano, Italy).
Amplification was performed with specific primers for
two classes of genes (table. 1): a) genes expressed in mes-
enchymal cells (SDF1, CXCR4, Oct-4, SCF, GATA-4, Vim,
FGF-5, Pax-6, NCAM, AFP, BMP-2) (26, 28); b) genes
expressed during osteogenic differentiation (COL1, ONC,
OPN, OCN, OPG, BSP and Runx2) [29-31]. Amplifica-
tions were carried out using 35 cycles of 95°C, 1 min; var-
iable annealing temperature (see Table 1), 1 min; 72°C, 1
min. RT-PCR products were separated in a 2% agarose gel
and visualized by Ethidium Bromide staining. Images
were captured using a Gel Doc 2000 (BioRad, CA, USA).
Cytogenetic investigation
For cytogenetic analysis, cultures carried out using proto-
col 2 were treated at day 30 with trypsin and 36–48 hours
colcemid. Metaphase chromosomes were stained with
GTG-banding and Giemsa. At least 20 metaphases were
examined for each sample.
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Table 1: Genes analyzed in RT-PCR experiments, primer sequences and annealing temperature.
Gene Gene symbol Primer Sequences Annealing temperature Size (bp)
Stromal cell-derived factor-1 SDF1 F – gacccgcgctcgtccgcc
R – cgggtcaatgcacacacttgtcta
57° 262
Chemokine (C-X-C motif) receptor 4 CXCR4 F – agctgttggctgaaaaggtgg
R – gcgcttctggtggcccttgga
60° 260
Octamer-binding transcription factor 4 Oct-4 F – cgt gaa gct gga gaa gga gaa gct g
R – caa ggg ccg cag ctc aca cat gtt c
60° 245
Stem cell factor SCF F – cca ttg atg cct tca agg ac
R – ctt cca gta taa ggc tcc aa
62° 275
GATA binding protein 4 GATA-4 F – ttc ctc ttc cct cct caa at
R – tca gcg tgt aaa ggc atc tg
60° 194
Vimentin Vim F – tca gcg tgt aaa ggc atc tg
R – cct tcg tga ata cca cg acct gc
56° 321
Fibroblast growth factor 5 FGF-5 F – gct gtg tct cag ggg att gta gga ata
R – tat cca aag cga aac ttg agt ctg ta
62° 434
Paired box 6 Pax-6 F – aga ttc aga tga ggc tca aa
R – aat tgg ttg gta gac act gg
60° 313
Neural cell adhesion molecule NCAM F – gag ggg gaa gat gcc gtg atg tg
R – ata ttc tgc ctg gcc cgg atg gta g
63° 269
Bone morphogenetic protein 2 BMP-2 F – ttg cgg ctg ctc agc atg tt
R – ttg cga gaa cag atg caa gat g
62° 315
Alpha-fetoprotein AFP F – gtg ctg cac ttc ttc ata tgc
R – tga cag cct caa gtt gtt cc
60° 218
Type I collagen COL1 F – ttcctttgcattcatctctca
R – caagtggaccaagcttcctt
58° 149
Osteonectin ONC F – gtctcactggctgtgttgga
R – aagacttgccatgtgggttc
60° 215
Osteopontin OPN F – aggaggaggcagagcaca
R – ctggtatggcacaggtgatg
60° 152
Osteocalcin OCN F – catgagagccctcaca
R – agagcgacaccctagac
58° 315
Osteoprotegerin OPG F – tgctgttcctacaaagttttacg
R – ctttgagtgctttagtgcgtg
60° 433
Bone sialoprotein BSP F – ctatggaaggacgccacgcct
R – catagccatcgtagccttgtcc
62° 578
Runt-related transcription factor 2 Runx2 F – gacagaagcttgatgactctaaacc
R – tctgtaatctgactctgtccttgt
60° 169
Glyceraldehyde-3-phosphate dehydrogenase GAPDH F – ccatggagaaggctggg
R – caaagttgtcatggatgacc
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